SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- NeoVolta Inc. (NASDAQ: NEOV), a U.S. energy-storage technology company, announced today that it is advancing a strategic collaboration with Luminia LLC (“Luminia”), a developer of solar and energy storage projects, under a non-binding framework that contemplates the potential development of a portfolio of solar-plus-storage projects planned across California, subject to the parties entering into definitive agreements.Luminia is developing multiple front-of-the-me ...

Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo groupThese findings suggest that urcosimod may have a positive impact on corneal nerve health in patients with neuropathic corneal painCorneal nerve imaging data from the Phase 2 NCP trial were analyzed using in vivo confocal microscopy LONDON and NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage bioph ...

Core Insights - HeartSciences Inc. has announced the commercial release of MyoVista Insights™ version 1.1, enhancing usability and clinical interpretation capabilities of ECG systems [1][2] - The platform is designed to improve workflow efficiency and expand interoperability across various ECG devices, making it a vendor and device agnostic solution [2][3] Product Features - MyoVista Insights is a cloud-native ECG management system that integrates AI ECG algorithm models from multiple partners, streamlining data management and improving workflow efficiency [2] - The updated version 1.1 provides a more intuitive platform for cardiac care, allowing clinicians to quickly interpret complex ECG data and make informed decisions [3] Market Position - Since its launch in May 2025, MyoVista Insights has received strong validation from early adopters and is currently in commercial discussions with several leading healthcare institutions [2] - The company aims to announce key customer deployments in the near term, indicating a positive market reception and potential growth opportunities [2]

Recognition alongside major OEMs underscores growing acceptance of integrated solar technology for commercial vehiclesMunich, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Sono Group N.V. (Nasdaq: SSM) (hereafter referred to as “Sono” or the “Company”, parent company to Sono Motors GmbH, hereafter referred to as “Sono Solar” or “Subsidiary”), the solar technology company, today announced that its subsidiary Sono Solar has been awarded the European Transport Prize for Sustainability 2026 (ETPN) for its solar solution fo ...

Core Viewpoint - Surgery Partners, Inc. plans to offer an additional $425 million of its 7.250% senior unsecured notes due 2032 to support general corporate purposes, including repaying outstanding borrowings [1][2] Group 1: Company Overview - Surgery Partners is a leading healthcare services company focused on high-quality, cost-effective surgical and ancillary care solutions, operating over 200 locations across 30 states [4] - The company was founded in 2004 and has become one of the largest and fastest-growing surgical services businesses in the United States [4] Group 2: Financial Offering Details - The additional notes will be guaranteed on a senior unsecured basis by each domestic wholly-owned subsidiary of the Issuer that guarantees its obligations under senior secured credit facilities [1] - The notes will be part of the same series as the previously issued 7.250% senior notes due 2032, originally issued in April 2024 [1]

H1 2025: 28% TTV Growth, 12% Revenue Growth, Liabilities Cut by $65M, Turkey Expansion SecuredLONDON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- RedCloud Holdings plc (Nasdaq: RCT) (“RedCloud” or the “Company”) the technology company building intelligent infrastructure for global trade today reported first half results, with RedAI platform. In H1, the company added another $1.2 billion in trading volume — up 28% year-over-year. Revenue for H1 2025 reached $17.9 million, up 12% year-over-year. For full year 2025, Re ...

Core Insights - Polyrizon Ltd. has announced promising results from its preclinical evaluation of an intranasal naloxone hydrogel formulation, highlighting its potential for improved drug delivery in emergency situations [1][4]. Group 1: Product Development - The company has demonstrated significantly enhanced mucoadhesion of its formulation on ex-vivo nasal tissue compared to a marketed product, with a p-value of less than 0.0001 [2]. - Permeation studies indicate that despite improved mucoadhesion, the hydrogel maintains rapid permeation kinetics comparable to existing naloxone products, ensuring fast action in emergencies [3][8]. - The results from stability, mucoadhesion, and permeability studies collectively position Polyrizon's naloxone hydrogel for further development stages [8]. Group 2: Market Context - The opioid crisis is escalating, with over 80,000 deaths annually in the U.S. due to opioid overdoses, necessitating improved naloxone delivery systems [5]. - The global naloxone market is projected to reach several billion dollars in the coming years, driven by public health initiatives and regulatory support for innovative products [5]. - Intranasal formulations are preferred for their ease of use and rapid action, making technologies like Polyrizon's hydrogel critical for enhancing treatment reliability during overdose events [5]. Group 3: Company Overview - Polyrizon specializes in developing innovative medical device hydrogels for intranasal delivery, aiming to create a barrier against viruses and allergens while enhancing drug retention [6]. - The company's proprietary technologies include Capture and Contain™ and Trap and Target™, focusing on improving bioadhesion and prolonged retention for drug delivery [6].

Core Insights - Biomerica, Inc. has received authorization from the Egyptian Drug Authority for its complete portfolio of rapid diagnostic tests, enhancing access to early detection tools for cancer and chronic diseases in Egypt [1][2][10] Product Portfolio - The authorized screening tests include those for colorectal disease, breast self-examination, prostate disease, kidney disease, and H. pylori infection, all designed for point-of-care use [1][3][7] - Tests provide quick results within minutes and do not require laboratory sample processing, making them suitable for diverse clinical and community settings [3][14] Market Need - Colorectal cancer is the 7th most common cancer in Egypt, with an incidence of approximately 5 to 10 cases per 100,000 persons per year, and a concerning trend of late-stage diagnoses [4] - Breast cancer is the most common cancer among women in Egypt, with an age-standardized incidence rate of about 55.4 per 100,000 persons per year, and poorer mortality outcomes due to late-stage diagnosis [5] - Prostate cancer ranks as the fourth most common cancer in Egypt, with increasing incidence rates [6] Health Statistics - Approximately 13% of adults in Egypt are living with chronic kidney disease, which has been among the top five causes of death from 2009 to 2019 [8] - H. pylori infection prevalence in Egypt ranges from 50% to 70%, affecting a significant portion of the population [8] Strategic Impact - The authorization supports national public health efforts to improve early disease detection, enhance health outcomes, and reduce long-term healthcare costs [9][10] - Biomerica's expansion in the Middle East and North Africa (MENA) region is reinforced by this authorization, aligning with global preventive care trends [11]

Core Insights - XBP Global Holdings, Inc. has entered into a five-year agreement with BG-Phoenics GmbH, valued at up to 21.5 million Euro, to provide workflow automation services in Germany's statutory accident insurance sector [1][2][4] Group 1: Agreement Details - The contract involves XBP Global transitioning the client's mail processing from paper-based workflows to AI-driven digital document management [2][4] - XBP Global will utilize its Intelligent Document Processing (IDP) Software platform to process and digitize up to 148 million pages during the contract period [3][4] Group 2: Strategic Positioning - This agreement enhances XBP Global's presence in the German public sector and reinforces its reputation as a strategic partner for technology-enabled document management services [2][4] - The engagement follows a competitive tender process and aligns with XBP Global's strategy to strengthen its foothold in regulated industries and key European markets [4] Group 3: Company Overview - XBP Global operates in 20 countries with approximately 11,000 professionals and partners with over 2,500 clients, including many Fortune 100 companies [6][7] - The company focuses on intelligent workflows and hyper-automation, leveraging its proprietary platforms and AI-driven automation to support digital transformations [7]

Core Insights - Cadrenal Therapeutics has acquired VLX-1005 and related 12-LOX assets from Veralox Therapeutics, enhancing its pipeline with a late-stage drug candidate aimed at the $40 billion global anticoagulation market [1][4] Company Overview - Cadrenal Therapeutics is focused on developing innovative therapeutics to address gaps in anticoagulation management for high-risk patient populations, with three clinical-stage assets including VLX-1005, tecarfarin, and frunexian [6] Product Details - VLX-1005 is a selective small-molecule inhibitor of 12-LOX, targeting immune platelet-mediated inflammation and addressing heparin-induced thrombocytopenia (HIT), which affects up to 5% of patients exposed to heparin [2][8] - The drug has received Orphan Drug Designation and Fast Track designation from the FDA, indicating its potential significance in treating rare conditions [4][8] Clinical Development - Phase 1 studies of VLX-1005 showed it was well tolerated with no serious adverse events, while a Phase 2 study indicated promising reductions in thromboembolic events among patients with suspected HIT [3][4] - The market for HIT treatment is estimated to reach $1 billion in the US and EU, highlighting the commercial potential of VLX-1005 [5] Acquisition Terms - The acquisition agreement includes upfront and milestone payments to Veralox contingent on future clinical and regulatory achievements, as well as royalties on global sales of VLX-1005 [5]